BioSpace News Archive

Pharm Country

Therap’s Medication Administration Tool Can Assist in Reducing Medication Errors

Therap’s reporting tools are used by Registered Nurses, LPNs, and other caregivers for minimizing medication errors. Therap’s certified electronic health record software is used widely by nurses working at agencies that support individuals with intellectual and developmental disabilities.

December 2, 2018
·
2 min read
Pharm Country

Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies

Novartis announced results of a retrospective, real-world evidence study in patients with immune thrombocytopenia (ITP) treated with Promacta® (eltrombopag), compared to other second-line therapies.

December 2, 2018
·
12 min read
Drug Development

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Eighty one percent overall response rate and 43% complete response rate observed in heavily pre-treated patients

December 2, 2018
·
4 min read
Drug Development

Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting

SY-1425 in Combination with Azacitidine Shows 63% Overall Response Rate and Rapid Onset of Clinical Responses in RARA or IRF8 Biomarker-Positive Newly Diagnosed Unfit AML Patients

December 2, 2018
·
11 min read
Drug Development

Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis

83% overall response rate, with evidence of deepening of response over time

December 2, 2018
·
15 min read
Drug Development

NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting

Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100%

December 2, 2018
·
6 min read
Pharm Country

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting

26-week data from the ongoing 52-week REFLECTIONS B328-06 study met its primary endpoint, demonstrating comparable safety and efficacy for patients with indolent follicular lymphoma

December 2, 2018
·
7 min read
Business

Record-breaking $11.2 million raised for St. Jude Children’s Research Hospital® at 17th annual St. Jude Memphis Marathon® Weekend

In its biggest year yet, St. Jude Memphis Marathon® Weekend presented by Juice Plus+® raised a record $11.2 million for kids at St. Jude Children’s Research Hospital®.

December 2, 2018
·
4 min read
Drug Development

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session

Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in statistically significant increased red blood cell transfusion independence compared to placebo

December 2, 2018
·
9 min read
Policy

European Medicines Agency Accepts Extension Marketing Authorisation Application for Review of Celltrion’s Remsima SC, the Subcutaneous Version of Remsima®

European Medicines Agency started to officially review ‘Remsima SC’; expecting European approval in the second half of next year

December 2, 2018
·
2 min read